Women's Health

ACP 2025: Lung cancer is rising among nonsmokers, especially women. Kim Sandler, MD, discusses future screening challenges, research insights, and the need to expand screening eligibility.

Gepotidacin is the first new oral antibiotic for uncomplicated urinary tract infections in 30 years, offering an alternative amid rising antibiotic resistance.

ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.

For the same level of baseline health, the increase in risk related to each of 8 key CV risk factors appears significantly higher in women than in men.

Three of the 5 osteoporosis screening tools recommended by the USPSTF for identifying osteoporosis in postmenopausal women aged 50 yo 64 years proved suboptimal.

Your daily dose of the clinical news you may have missed.

The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.

Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.

The 2 analyses of data on fertility and infant mortality were conducted in the first 14 states to impose complete or 6-week bans after the Dobbs decision in June 2022.

A family medicine specialist who works with cancer survivorship highlights findings of a study that illustrate how effective screening is and how treatment has changed.

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.

World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.

Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

FDA action date set for July 26, 2025.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

Your daily dose of the clinical news you may have missed.

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

The addition, based on an approved update to labeling, expands to 4 the recommended vaccination options that health care professionals can offer to pregnant people.

The potential adverse outcomes include asthma, food allergies, cerebral palsy, and cancer, according to a recent systematic review and meta-analysis.

Your daily dose of the clinical news you may have missed.

How does alcohol figure in to American holiday celebrations? We checked with Alcohol.org for this quiz. Are answers what you expect?

Comments on the draft recommendation can be submitted through December 23, 2024.